1. Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?

   • Thomas B. Karasic
   • Mark A. Rosen
   • Peter J. O’Dwyer

   Review Article 18 July 2017 Pages: 661 - 671

   

2. Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition

   • Qiong Yang
   • Florian Puhm
   • Christian Nanoff

   Original Article Open access 04 August 2017 Pages: 673 - 684

   

3. Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer

   • Shengshi Huang
   • Di Wang
   • Yikang Shi

   Original Article 04 August 2017 Pages: 685 - 696

   

4. The concept of platinum sensitivity could be applied to recurrent cervical cancer: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group

   • Munetaka Takekuma
   • Keita Mori
   • Toru Sugiyama

   Original Article 07 August 2017 Pages: 697 - 705

   

5. A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer

   • Naoki Uemura
   • Shohei Kikuchi
   • Junji Kato

   Original Article 28 August 2017 Pages: 707 - 713

   

6. Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma

   • Michael A. Badruddoja
   • Marjorie Pazzi
   • Michael Malek Ahmadi

   Original Article 14 August 2017 Pages: 715 - 721

   

7. Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect

   • Tamás Solymosi
   • Zsolt Ötvös
   • Hristos Glavinas

   Original Article 03 August 2017 Pages: 723 - 728

   

8. Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review

   • Jung Han Kim
   • Bum Jun Kim
   • Hyeong Su Kim

   Original Article 05 August 2017 Pages: 729 - 735

   

9. Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin

   • N. Blank
   • I. Laskov
   • L. Rudski

   Original Article 11 August 2017 Pages: 737 - 743

   

10. Allicin ameliorates doxorubicin-induced cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis

    • Mohamed M. Abdel-Daim
    • Omnia E. kilany
    • Amal A. M. Ahmed

    Original Article 07 August 2017 Pages: 745 - 753

    

11. A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men

    • Richard Markus
    • Vincent Chow
    • Vladimir Hanes

    Original Article Open access 01 September 2017 Pages: 755 - 763

    

12. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells

    • Azam Rajabpour
    • Ali Afgar
    • Ladan Teimoori-Toolabi

    Original Article 08 September 2017 Pages: 765 - 775

    

13. Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer

    • Katsuki Danno
    • Taishi Hata
    • Colorectal Cancer Treatment Group (MCSGO)

    Original Article 19 August 2017 Pages: 777 - 785

    

14. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value

    • Keith M. Skubitz
    • Anne H. Blaes
    • Gary S. Francis

    Original Article 30 August 2017 Pages: 787 - 798

    

15. Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea

    • Kyong Joo Lee
    • Jae Hee Cho
    • Woo Jin Lee

    Original Article 07 September 2017 Pages: 799 - 805

    

16. Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy

    • Shigenori Kadowaki
    • Toshiki Masuishi
    • Kei Muro

    Original Article 18 August 2017 Pages: 807 - 813

    

17. Superactive human leptin antagonist (SHLA), triple Lan1 and quadruple Lan2 leptin mutein as a promising treatment for human folliculoma

    • E. Fiedor
    • E. L. Gregoraszczuk

    Original Article Open access 31 August 2017 Pages: 815 - 827

    

18. Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia

    • Islem Ben Hassine
    • Hanene Gharbi
    • Samia Menif

    Original Article 23 August 2017 Pages: 829 - 839

    

19. Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer

    • Nao Tagawa
    • Erika Sugiyama
    • Hitoshi Sato

    Original Article 01 September 2017 Pages: 841 - 849

    

20. Significance of glucocorticoid receptor expression in patients with non-small cell lung cancer treated with pemetrexed-based chemotherapy

    • Xin-min Zhao
    • Jing Zhao
    • Jia-lei Wang

    Clinical Trial Report 28 July 2017 Pages: 851 - 860

    

21. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition

    • Gayathri Srinivasan
    • Gurjit Singh Sidhu
    • Robert Hromas

    Short Communication Open access 29 July 2017 Pages: 861 - 867

    

22. Continuous low plasma concentrations of everolimus provides equivalent efficacy to oral daily dosing in mouse xenograft models of human cancer

    • Laurent Laborde
    • Fatos Oz
    • Paul McSheehy

    Short Communication 04 August 2017 Pages: 869 - 878

    

23. Optimism and the continued promise of maintenance chemotherapy

    • John P. Micha
    • Bram Goldstein
    • Maurie Markman

    Letter to the Editor 07 September 2017 Pages: 879 - 880